367 related articles for article (PubMed ID: 28473441)
1. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
[TBL] [Abstract][Full Text] [Related]
2. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
van Capelleveen JC; Lee SR; Verbeek R; Kastelein JJP; Wareham NJ; Stroes ESG; Hovingh GK; Khaw KT; Boekholdt SM; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(6):1493-1501.e11. PubMed ID: 30249512
[TBL] [Abstract][Full Text] [Related]
3. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
[TBL] [Abstract][Full Text] [Related]
4. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
El Harchaoui K; van der Steeg WA; Stroes ES; Kuivenhoven JA; Otvos JD; Wareham NJ; Hutten BA; Kastelein JJ; Khaw KT; Boekholdt SM
J Am Coll Cardiol; 2007 Feb; 49(5):547-53. PubMed ID: 17276177
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
7. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
Olivieri O; Chiariello C; Martinelli N; Castagna A; Speziali G; Girelli D; Pizzolo F; Bassi A; Cecconi D; Robotti E; Manfredi M; Conte E; Marengo E
Clin Chem Lab Med; 2018 Aug; 56(9):1542-1550. PubMed ID: 29652662
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.
Cao YX; Zhang HW; Jin JL; Liu HH; Zhang Y; Xu RX; Gao Y; Guo YL; Zhu CG; Hua Q; Li YF; Santos RD; Wu NQ; Li JJ
J Lipid Res; 2020 Sep; 61(9):1254-1262. PubMed ID: 32641433
[TBL] [Abstract][Full Text] [Related]
9. High-density lipoprotein particle size and concentration and coronary risk.
El Harchaoui K; Arsenault BJ; Franssen R; Després JP; Hovingh GK; Stroes ES; Otvos JD; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
Ann Intern Med; 2009 Jan; 150(2):84-93. PubMed ID: 19153411
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.
Mendivil CO; Rimm EB; Furtado J; Chiuve SE; Sacks FM
Circulation; 2011 Nov; 124(19):2065-72. PubMed ID: 21986282
[TBL] [Abstract][Full Text] [Related]
11. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.
Mendoza S; Trenchevska O; King SM; Nelson RW; Nedelkov D; Krauss RM; Yassine HN
J Clin Lipidol; 2017; 11(1):224-233.e2. PubMed ID: 28391889
[TBL] [Abstract][Full Text] [Related]
12. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.
Mendivil CO; Rimm EB; Furtado J; Sacks FM
J Am Heart Assoc; 2013 May; 2(3):e000130. PubMed ID: 23672999
[TBL] [Abstract][Full Text] [Related]
14. High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis).
Aroner SA; Koch M; Mukamal KJ; Furtado JD; Stein JH; Tattersall MC; McClelland RL; Jensen MK
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29540426
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
16. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
Aroner SA; Furtado JD; Sacks FM; Tsai MY; Mukamal KJ; McClelland RL; Jensen MK
Diabetologia; 2019 Jun; 62(6):981-992. PubMed ID: 30949716
[TBL] [Abstract][Full Text] [Related]
18. High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals.
Yamamoto R; Sacks FM; Hu FB; Rosner B; Furtado JD; Aroner SA; Ferrannini E; Baldi S; Kozakova M; Balkau B; Natali A; Jensen MK;
Atherosclerosis; 2018 Feb; 269():92-99. PubMed ID: 29351856
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
20. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
